FAS and obesity disorder: MCSFAs, such as caproic acid (6:0) and caprylic acid (8:0), have been shown in a cellular model to reduce the activity of fatty acid synthase (FAS), a primary enzyme of de novo lipogenesis that may contribute to the development of obesity and non-alcoholic fatty liver disease (NAFLD) [30].